|
NL154598B
(nl)
|
1970-11-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
|
|
US3817837A
(en)
|
1971-05-14 |
1974-06-18 |
Syva Corp |
Enzyme amplification assay
|
|
US3939350A
(en)
|
1974-04-29 |
1976-02-17 |
Board Of Trustees Of The Leland Stanford Junior University |
Fluorescent immunoassay employing total reflection for activation
|
|
US3996345A
(en)
|
1974-08-12 |
1976-12-07 |
Syva Company |
Fluorescence quenching with immunological pairs in immunoassays
|
|
US4277437A
(en)
|
1978-04-05 |
1981-07-07 |
Syva Company |
Kit for carrying out chemically induced fluorescence immunoassay
|
|
US4275149A
(en)
|
1978-11-24 |
1981-06-23 |
Syva Company |
Macromolecular environment control in specific receptor assays
|
|
US4366241A
(en)
|
1980-08-07 |
1982-12-28 |
Syva Company |
Concentrating zone method in heterogeneous immunoassays
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
FR2646438B1
(fr)
|
1989-03-20 |
2007-11-02 |
Pasteur Institut |
Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
DE69127627T2
(de)
|
1990-08-29 |
1998-02-19 |
Genpharm Int |
Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
ATE297465T1
(de)
|
1991-11-25 |
2005-06-15 |
Enzon Inc |
Verfahren zur herstellung von multivalenten antigenbindenden proteinen
|
|
ATE408012T1
(de)
|
1991-12-02 |
2008-09-15 |
Medical Res Council |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
|
EP0640094A1
(en)
|
1992-04-24 |
1995-03-01 |
The Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
CA2290485C
(en)
|
1997-05-21 |
2008-08-05 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US7083950B2
(en)
|
1998-09-25 |
2006-08-01 |
Regeneron Pharmaceuticals, Inc. |
High affinity fusion proteins and therapeutic and diagnostic methods for use
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
|
JP2007530526A
(ja)
|
2004-03-26 |
2007-11-01 |
ファイザー・プロダクツ・インク |
抗ｃｔｌａ−４抗体の使用
|
|
AU2005271523B2
(en)
*
|
2004-08-03 |
2011-09-15 |
Dyax Corp. |
hk1-binding proteins
|
|
AU2008323206B2
(en)
*
|
2007-11-12 |
2014-08-14 |
U3 Pharma Gmbh |
AXL antibodies
|
|
DK2356270T3
(da)
|
2008-11-07 |
2016-12-12 |
Fabrus Llc |
Kombinatoriske antistofbiblioteker og anvendelser deraf
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
EP2432488A4
(en)
*
|
2009-03-20 |
2014-01-08 |
Amgen Inc |
SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
|
|
US8841424B2
(en)
|
2009-05-11 |
2014-09-23 |
U3 Pharma Gmbh |
Humanized AXL antibodies
|
|
EP2486058A1
(en)
|
2009-10-09 |
2012-08-15 |
Sanofi |
Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
|
|
EP2582729A4
(en)
*
|
2010-06-18 |
2014-05-28 |
Hoffmann La Roche |
ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
|
|
BR112013032899A2
(pt)
*
|
2011-06-22 |
2017-01-24 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
anticorpos anti-axl e utilizações dos mesmos
|
|
US9249228B2
(en)
|
2011-06-22 |
2016-02-02 |
Oribase Pharma |
Anti-Axl antibodies and uses thereof
|
|
US20140121126A1
(en)
|
2012-10-25 |
2014-05-01 |
Memorial Sloan-Kettering Cancer Center |
Methods of detecting axl and gas6 in cancer patients
|
|
US9624308B2
(en)
*
|
2012-11-05 |
2017-04-18 |
Pierre Fabre Medicament |
Antigen binding proteins
|
|
EP4679095A2
(en)
|
2015-05-18 |
2026-01-14 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
JP6857138B2
(ja)
*
|
2015-05-18 |
2021-04-14 |
アジェンシス，インコーポレイテッド |
Ａｘｌタンパク質に結合する抗体
|
|
US11136399B2
(en)
*
|
2016-07-14 |
2021-10-05 |
Institute Of Biophysics, Chinese Academy Of Sciences |
Type I interferon receptor antibody and use thereof
|
|
IL296224A
(en)
*
|
2020-03-09 |
2022-11-01 |
Abcellera Biologics Inc |
Antibodies against corona virus and methods of use
|
|
WO2022155324A1
(en)
*
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|